EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Major depression: emerging therapeutics

Srijan Sen, Gerard Sanacora

Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · 2008-06 · 75 (3) · 204-225

DOI: 10.1002/msj.20043 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, online erschienen am 26.08.2008. Verfasst von Srijan Sen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 230 Literaturangaben. Gefördert von: NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The first effective antidepressants, monoamine oxidase inhibitors and tricyclic antidepressants, were identified 50 years ago, largely through serendipity. These medications were found to improve mood in a little more than half of depressed patients after a few weeks of chronic use. Almost all antidepressants prescribed today were developed through minor modifications of these original antidepressants and, like monoamine oxidase inhibitors and tricyclic antidepressants, act primarily through monoaminergic mechanisms. Although there have been improvements in side‐effect profiles and overdose toxicity, these newer medications have not provided substantial advances in the efficacy and speed of the antidepressant effect for patients. Over the last 2 decades, our understanding of the neurobiology underlying depression has expanded exponentially. Given this expansion, we may be nearing an inflection point in antidepressant drug development, at which useful medicines will be designed through a rational understanding of the biological systems. In this review, we discuss the biological basis and preclinical and clinical evidence for a series of promising classes of antidepressants developed primarily out of a pathophysiologically informed approach. Mt Sinai J Med 75:203–224, 2008. © 2008 Mount Sinai School of Medicine

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amino AcidsAntidepressive AgentsMajor Depressive DisorderGlutamic AcidHumansNerve Growth FactorsReceptors, AMPAReceptors, GABA

Substanzen

Amino AcidsAntidepressive AgentsNerve Growth FactorsReceptors, AMPAReceptors, GABAGlutamic Acid

Autor:innen und Institutionen

  • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.

Förderung

  • NIMH NIH HHS

Zitieren

APA

Sen, S., & Sanacora, G. (2008). Major depression: emerging therapeutics. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 75(3), 204-225. https://doi.org/10.1002/msj.20043

Vancouver

Sen S, Sanacora G. Major depression: emerging therapeutics. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine. 2008;75(3):204-225. doi:10.1002/msj.20043

BibTeX
@article{Sen2008,
  author = {Sen, Srijan and Sanacora, Gerard},
  title = {Major depression: emerging therapeutics},
  journal = {Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine},
  year = {2008},
  volume = {75},
  number = {3},
  pages = {204--225},
  doi = {10.1002/msj.20043}
}
Kostenlos starten →